Current situation of the treatment of heart failure in Brazil;Situação atual do tratamento da insuficiência cardíaca no Brasil

Arquivos Brasileiros de Cardiologia

Volumn 89, Issue 4, 2007, Pages

  Mady, Charles ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; SPIRONOLACTONE;

AORTA VALVE REGURGITATION; CARDIOMYOPATHY; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE SEVERITY; ENDOMETRIUM BIOPSY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIFESTYLE; MORBIDITY; MORTALITY; POPULATION; RHEUMATIC DISEASE; SHORT SURVEY; SYMPTOMATOLOGY;

EID: 37349058192     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Ministério da Saúde. Datasus: morbidade hospitalar - sistema de informações hospitalares do SUS (SIH/SUS). Brasília; 2003.
2. Rossi Neto JM. A dimensão do problema da insuficiência cardíaca do Brasil e do mundo. Rev Soc Cardiol Estado de São Paulo. 2004; 14: 1-10.
3. Tavares LR, Victer H, Linhares JM, de Barros CM, Oliveira MV, Pacheco LC, et al. Epidemiologia da insuficiência cardíaca descompensada em Niterói - Projeto EPICA - Niterói. Arq Bras Cardiol. 2004; 82 (2): 121-4.
4. Albanesi Filho FM. Insuficiência cardíaca no Brasil. Arq Bras Cardiol. 1998; 71: 561-2.
5. The CONSENSUS Trial Study Group. N Engl J Med. 1987; 316 (23): 1429-35.
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341 (10): 709-17.
7. Ramires FJ, Salemi VM, Ianni BM, Fernandes F, Martins DG, Billate A, et al. Aldosterone antagonism in an inflammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst. 2006; 7: 162-7.
8. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000; 342: 1077-84.
9. Mady C, Cardoso RHA, Pereira Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival pacients with congestive heart failure due to Chagas' cardiomyopathy. Circulation. 1994; 90: 3098-102.
10. Soufen HN. Análise histológica e molecular da fibrose miocárdica em pacientes portadores de miocardiopatia dilatada de diferentes etiologias. [Tese]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 2002.
11. Mady C, Ianni BM, Arteaga E, Montes GS, Caldini EG, Andrade G, et al. Relation between interstitial myocardial collagen and the degree of clinical impairment in Chagas' disease. Am J Cardiol. 1999; 84 (3): 354-6.
12. Mady C. Riscos e benefícios da biopsia endomiocárdica de ventrículo direito (editorial). Arq Bras Cardiol. 1998; 70 (3): 185-6.
13. Nigri M, Rochitte CE, Tarasoutchi F, Spina GS, Parga JR, Avila LF, et al. Valvopatia aórtica crônica grave sintomática: estudo comparado da ressonância magnética cardíaca e ecocardiografia. Arq Bras Cardiol. 2006; 86: 145-9.
14. Nigri M, Rochitte CE, Tarasoutchi F, Spina GS, Sampaio RO, Cardoso LF, et al. Myocardial fibrosis detected by MRI and biopsy is associated with worse left ventricular function in patients with severe chronic aortic valve disease [abstract]. Circulation. 2003; 108: 567.
15. Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail. 2003; 9: 311-7.
16. Mady C, Ianni BM, Arteaga E, Salemi VMC, Frimm C de C. Maximal functional capacity in patients with Chagas' cardiomyopathy without congestive heart failure. J Card Fail. 2000; 6: 220-4.
17. Ianni BM, Mady C. Terapêutica da forma crônica da doença de Chagas: é eficaz o tratamento etiológico? Arq Bras Cardiol. 1998; 70: 59-61.
18. Tempone AG, Sartorelli P, Mady C, Fernandes F. Natural products to antitrypanosomal drugs: an overview of new drug prototypes for American Trypanosomiasis. Cardiovascular & Hematological Agents in Medicinal Chemistry 2007; 5 (no prelo)
19. Arteaga E, Pereira Barretto AC, Mady C, Higuchi ML, Fiorelli AI, Bellotti G, et al. Miocardite linfocitária: resposta ao tratamento com drogas imunossupressoras. Arq Bras Cardiol. 1990; 55 (3): 161-5.
20. Mady C, D'Avila ALB. Miocardite linfocitária ativa. Rev Soc Cardiol Estado de São Paulo. 1992; 2: 20-4.
21. Mady C. Estado atual do uso clínico do digital (editorial). Arq Bras Cardiol. 1994; 63: 353-4.